OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa

Who May Qualify: - Agreement to come to the clinic for all follow-up evaluations - Provision of willing to sign a consent form and assent (as appropriate) - Residency within approximately 30 km of the study clinic - Negative blood smear for malaria (all sites) - For Children and adolescents living with HIV - Confirmed HIV infection - On DTG-based regimen for ≥14 days - For HIV-uninfected children - documentation of HIV-negative status by at least 1 assay Who Should NOT Join This Trial: - Significant comorbidities such as malignancy, active TB, chronic/active hepatitis B/C, diabetes, severe acute malnutrition, mitochondrial disorders - Receipt of known CYP interacting drugs at enrolment (except HAART) - see list of disallowed medications - Anemia defined by hemocue (Hb \< 7.0) at the time of enrolment - Signs of uncomplicated or severe malaria at the time of enrollment - Prior intolerance to AL or AS-AQ (for those in Busia only) - Pregnancy at enrolment (testing done at enrollment for all those of child-bearing age) - Concurrent enrolment in another research study Always talk to your doctor about whether this trial is right for you.